CYP2J2 Antibody (E-6): sc-137100
- CYP2J2 Antibody (E-6) is a mouse monoclonal IgG2b κ, cited in 1 publications, provided at 200 µg/ml
- raised against amino acids 243-302 mapping within an internal region of CYP2J2 of human origin
- recommended for detection of CYP2J2 of human origin by WB, IP, IF and ELISA
- m-IgG2b BP-HRP and m-IgGκ BP-HRP are the preferred secondary detection reagents for CYP2J2 Antibody (E-6) for WB applications. These reagents are now offered in bundles with CYP2J2 Antibody (E-6) (see ordering information below).
CYP2J2 Antibody (E-6) is a mouse monoclonal IgG2b antibody that detects CYP2J2 in human samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). CYP2J2, also known as cytochrome P450 2J2, is a crucial member of the cytochrome P450 superfamily, primarily localized to the endoplasmic reticulum and microsomal membranes. CYP2J2 plays a vital role in the metabolism of arachidonic acid, converting it into epoxyeicosatrienoic acids, which are significant regulators of cardiovascular function and vascular tone. CYP2J2′s ability to epoxidize endogenous cardiac arachidonic acid pools into four distinct isoforms of epoxyeicosatrienoic acid underscores its importance in maintaining cardiovascular homeostasis. CYP2J2 is predominantly expressed in the heart, with lower expression levels in the liver, colon, and kidneys. Furthermore, CYP2J2 up-regulation through a c-Jun responsive pathway has been linked to the promotion of neoplastic characteristics in certain carcinoma cells, suggesting potential involvement in carcinogenesis. Anti-CYP2J2 antibody (E-6) is an essential tool for researchers investigating this protein′s role in both normal physiology and disease states.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
CYP2J2 Antibody (E-6) References:
- Endothelium-specific CYP2J2 overexpression attenuates age-related insulin resistance. | Yang, Y., et al. 2018. Aging Cell. 17: PMID: 29318723
- CYP2J2 Expression in Adult Ventricular Myocytes Protects Against Reactive Oxygen Species Toxicity. | Evangelista, EA., et al. 2018. Drug Metab Dispos. 46: 380-386. PMID: 29343610
- Regulation of CYP2J2 and EET Levels in Cardiac Disease and Diabetes. | Aliwarga, T., et al. 2018. Int J Mol Sci. 19: PMID: 29966295
- CYP2J2/EET reduces vulnerability to atrial fibrillation in chronic pressure overload mice. | Li, X., et al. 2020. J Cell Mol Med. 24: 862-874. PMID: 31749335
- Anthracycline derivatives inhibit cardiac CYP2J2. | Kim, JS., et al. 2022. J Inorg Biochem. 229: 111722. PMID: 35078036
- Cardiomyocyte-specific CYP2J2 and its therapeutic implications. | Valencia, R., et al. 2022. Expert Opin Drug Metab Toxicol. 18: 423-439. PMID: 35997132
- Endothelial CYP2J2 overexpression restores the BRB via METTL3-mediated ANXA1 upregulation. | Zhao, B., et al. 2022. FASEB J. 36: e22619. PMID: 36269280
- Investigating the association between CYP2J2 inhibitors and QT prolongation: a literature review. | Wiley, AM., et al. 2024. Drug Metab Rev. 56: 145-163. PMID: 38478383
- CYP2J2-mediated metabolism of arachidonic acid in heart: A review of its kinetics, inhibition and role in heart rhythm control. | Leow, JWH. and Chan, ECY. 2024. Pharmacol Ther. 258: 108637. PMID: 38521247
- Paricalcitol ameliorates diabetic nephropathy by promoting EETs and M2 macrophage polarization and inhibiting inflammation by regulating VDR/CYP2J2 axis. | Tang, S., et al. 2024. FASEB J. 38: e70108. PMID: 39441644
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
CYP2J2 Antibody (E-6) | sc-137100 | 200 µg/ml | $322.00 | |||
CYP2J2 Antibody (E-6): m-IgGκ BP-HRP Bundle | sc-534655 | 200 µg Ab; 40 µg BP | $361.00 | |||
CYP2J2 Antibody (E-6): m-IgG2b BP-HRP Bundle | sc-549276 | 200 µg Ab; 10 µg BP | $361.00 |